Estimate Pancreatic Decline
An Innovative Approach to Combating Diabetes
Screening and Prevention
DIABETES TYPE II
>1/2 Billion w/ Diabetes 2 (2M New Cases/Year)
DIABETES TYPE I
Immunotherapy companion diagnostics
10% of pregnacies
Screening for after-birth effects of gestational diabetes
How it works: a unique innovation in diabetes
Minimally-invasive dynamic mirror of
Epigenetic Biomarker Panel
Combination of tissue specific biomarkers (not a single one) providing a stronger predictive
Automated Machine Learning
Use our LPancreas dashboard and our advanced AI modeling
LPancreas is a product of ABCureD PC.
The test demonstrates the highest ever reported performance for a model in detecting diabetes. See Karaglani et al., JCM 2022.
The practitioner has an insight about the progress of patient’s pancreatic decline, indicative of the progress of the pathology.